Team

Michael Grey
Venture Partner and SAB Member

Mike has over 30 years of experience in the biopharmaceutical industry and prior to joining Pappas Ventures was President and CEO of Auspex Pharmaceuticals from January 2009. Mike was previously CEO of SGX Pharmaceuticals (formerly Structural GenomiX) and eventually sold the company to Eli Lilly. Prior to joining SGX in 2001, Mike served as President and CEO of Trega Biosciences until its acquisition by Lion Bioscience. He also served as President of BioChem Therapeutics, the pharmaceutical arm of BioChem Pharma, from 1994 to 1998. From 1974 to 1993, Mike served in various roles with Glaxo Holdings plc and Glaxo Inc., including positions as Vice President, Corporate Development, and Director, International Licensing. Mike currently serves on the board of directors of Achillion Pharmaceuticals and BioMarin Pharmaceutical.

Education

University of Nottingham, United Kingdom (B.Sc. in Chemistry)